Lexicon Pharma Offers 'A 2-Part Story With Upside Prospects' By: Benzinga via Benzinga October 07, 2016 at 10:45 AM EDT H.C. Wainwright has started coverage of Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) with a Buy rating and $26 price target on potential ... Read More >> Related Stocks: Lexicon Pharmaceutcl Sanofi-Aventis S.A. ADR